# A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

> **NCT01310036** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 208 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT01310036
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-30
- **Primary completion:** 2014-02-14
- **Final completion:** 2016-12-30
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2018-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01310036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01310036, "A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01310036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*